(Total Views: 562)
Posted On: 02/27/2021 5:19:53 PM
Post# of 154105
CTMedic,
Thanks for this stat.
“SAEs were reduced from and incidence of 39% in placebo to 14% in CD10, a reduction of 64%.”
Read More: https://investorshangout.com/post/view?id=606...z6niEVhaGH
I was trying to recall this the other day. Dr Jay said he has been apart of several hundred drug studies, and never had the trial drug had LESS SAEs than Placebo. He said it never happens.
To my ear what this means is, Leronlimab is fixing stuff that wasn’t part of the study. It’s fixing stuff that the SOC isn’t even fixing. For instance, if CD10 was studying COVID-19, Leronlimab is also curing a trial patient‘s tumorous cancer, or NASH, etc. Fill in the _______.
Thanks for this stat.
“SAEs were reduced from and incidence of 39% in placebo to 14% in CD10, a reduction of 64%.”
Read More: https://investorshangout.com/post/view?id=606...z6niEVhaGH
I was trying to recall this the other day. Dr Jay said he has been apart of several hundred drug studies, and never had the trial drug had LESS SAEs than Placebo. He said it never happens.
To my ear what this means is, Leronlimab is fixing stuff that wasn’t part of the study. It’s fixing stuff that the SOC isn’t even fixing. For instance, if CD10 was studying COVID-19, Leronlimab is also curing a trial patient‘s tumorous cancer, or NASH, etc. Fill in the _______.
(6)
(1)
